TY - JOUR
T1 - Towards a new Value-based scenario for the management of dementia in Italy: a SINdem delphi consensus study
AU - Marra, Camillo
AU - Beccia, Flavia
AU - Caffarra, Paolo
AU - L'Abbate, Federica
AU - Agosta, Federica
AU - Benussi, Alberto
AU - Bonanni, Laura
AU - Bruni, Amalia C
AU - Bruno, Giuseppe
AU - Cappa, Stefano F
AU - Cerami, Chiara
AU - Di Lorenzo, Francesco
AU - Ferrarese, Carlo
AU - Galimberti, Daniela
AU - Guarnieri, Biancamaria
AU - Mariani, Claudio
AU - Nacmias, Benedetta
AU - Pantoni, Leonardo
AU - Piccoli, Tommaso
AU - Perani, Daniela
AU - Rainero, Innocenzo
AU - Tagliavini, Fabrizio
AU - Venneri, Annalena
AU - Boccia, Stefania
AU - Cagnin, Annachiara
AU - Calabrò, Giovanna Elisa
AU - Bozzali, Marco
PY - 2025
Y1 - 2025
N2 - This national expert-based Delphi-consensus aims at formulating recommendations on the management of dementia care in Italy. This effort seems important and timely given in light of a new scenario arising from a new biological definition of Alzheimer's disease (AD) and the availability of disease-modifying treatments (DMTs). Methods the Steering Committee of the Italian Neurological Society for dementia (SINdem) created appropriate statements. Invited SINdem experts were requested to vote on the statements according to a modified three-round Delphi method. Only those statements reaching Grade A (full agreement >= 75%) or B (overall agreement >= 80% and full disagreement < 5%) were included in the final document. Round answers' consistency was graded using the Cohen's k and within-class correlation coefficient. Results Forty-six experts voted on 20 statements, which focused on the following aspects: i) organization of care services from early diagnosis to the management of advanced clinical stages; ii) access to biomarkers for a biological diagnosis of AD; iii) requirements necessary for the administration of DMTs; iv) main actors and pathways for the management of patients suffering from cognitive disorders. At the end of the process, 4 statements (20%) received a Grade A consensus, while 16 (80%) reached a Grade B consensus. Although the responses reflect heterogeneity among Italian regions, there was a fair degree of consistency for all statements. Conclusion The high strength of this expert-based Delphi-consensus may offer guidance for improving the patient's journey of individuals with cognitive decline from a biological diagnosis to DMTs administration and may possibly offer hints to the Health Systems on dementia.
AB - This national expert-based Delphi-consensus aims at formulating recommendations on the management of dementia care in Italy. This effort seems important and timely given in light of a new scenario arising from a new biological definition of Alzheimer's disease (AD) and the availability of disease-modifying treatments (DMTs). Methods the Steering Committee of the Italian Neurological Society for dementia (SINdem) created appropriate statements. Invited SINdem experts were requested to vote on the statements according to a modified three-round Delphi method. Only those statements reaching Grade A (full agreement >= 75%) or B (overall agreement >= 80% and full disagreement < 5%) were included in the final document. Round answers' consistency was graded using the Cohen's k and within-class correlation coefficient. Results Forty-six experts voted on 20 statements, which focused on the following aspects: i) organization of care services from early diagnosis to the management of advanced clinical stages; ii) access to biomarkers for a biological diagnosis of AD; iii) requirements necessary for the administration of DMTs; iv) main actors and pathways for the management of patients suffering from cognitive disorders. At the end of the process, 4 statements (20%) received a Grade A consensus, while 16 (80%) reached a Grade B consensus. Although the responses reflect heterogeneity among Italian regions, there was a fair degree of consistency for all statements. Conclusion The high strength of this expert-based Delphi-consensus may offer guidance for improving the patient's journey of individuals with cognitive decline from a biological diagnosis to DMTs administration and may possibly offer hints to the Health Systems on dementia.
KW - Alzheimer care management
KW - Biological diagnosis
KW - Delphi consensus
KW - Dementia
KW - Disease modifying drugs
KW - Italy
KW - Alzheimer care management
KW - Biological diagnosis
KW - Delphi consensus
KW - Dementia
KW - Disease modifying drugs
KW - Italy
UR - https://publicatt.unicatt.it/handle/10807/314383
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=105005418156&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105005418156&origin=inward
U2 - 10.1007/s10072-025-08143-5
DO - 10.1007/s10072-025-08143-5
M3 - Article
SN - 1590-1874
VL - 2025
SP - N/A-N/A
JO - Neurological Sciences
JF - Neurological Sciences
IS - 16
ER -